Clinigen Group plc Grant of Share Options and PDMR notification (9352F)
01 March 2018 - 8:00PM
UK Regulatory
TIDMCLIN
RNS Number : 9352F
Clinigen Group plc
01 March 2018
1 March 2018
Grant of Share Options and PDMR notification
Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Company"),
announces that, on 1 March 2018, Debra Ainge (Chief Operating
Officer of the Company and a PDMR) was granted share options over a
total of 17,888 ordinary shares of 0.1 pence each ("Ordinary
Shares") under the Clinigen Group Long Term Incentive Plan 2015.
These options are nil cost options intended to vest on 16 October
2020 subject to the achievement of certain performance
criteria.
The additional share options granted to Debra Ainge relate to
the completion of the acquisition of Quantum Pharma plc and her
assuming additional responsibility for the early access and 'on
demand' access businesses within Unlicensed Medicines.
Director/PDMR Number Total number Total number Total number
of share of share of ordinary of ordinary
options options shares shares
granted now held now held (excluding
share options)
as % issued
share capital
--------------- ---------- ------------- ------------- ----------------
Debra Ainge 17,888 66,406 10,254 0.01%
--------------- ---------- ------------- ------------- ----------------
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by person
discharging managerial responsibilities.
1 Details of the person discharging
managerial responsibilities/person
closely associated
---- ------------------------------------------------------
a) Name Debra Ainge
---- -------------------- --------------------------------
2 Reason for the notification
---- ------------------------------------------------------
a) Position/status Chief Operating Officer
- PDMR
---- -------------------- --------------------------------
b) Initial Initial Notification
notification
/Amendment
---- -------------------- --------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform,
auctioneer or auction monitor
---- ------------------------------------------------------
a) Name Clinigen Group plc
---- -------------------- --------------------------------
b) Legal Entity N/A
Identifier
---- -------------------- --------------------------------
4 Details of the transaction(s): section
to be repeated for (i) each type
of instrument; (ii) each type of
transaction; (iii) each date; and
(iv) each place where transactions
have been conducted
---- ------------------------------------------------------
a) Description Ordinary shares of 0.1 pence
of the financial each
instrument, GB00B89J2419
type of
instrument
Identification
code
---- -------------------- --------------------------------
b) Nature of Grant of Options
the transaction
---- -------------------- --------------------------------
c) Currency GBP
---- -------------------- --------------------------------
d) Price(s) Exercise No. of shares
and volume(s) Price
---- -------------------- ------------- -----------------
Nil 17,888
--------------------------------------- -----------------
e) Aggregated 17,888
information Nil
- Aggregated
volume
- Price
- Aggregated
total
---- -------------------- --------------------------------
f) Date of 1 March 2018
the transaction
---- -------------------- --------------------------------
g) Place of London Stock Exchange, AIM
the transaction
---- -------------------- --------------------------------
-Ends-
Contact details
Clinigen Group plc Tel: +44 (0) 1283
495010
Shaun Chilton, Group Chief
Executive Officer
Martin Abell, Group Chief
Financial Officer
Numis Securities Limited Tel: +44 (0) 20
7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Tom Ballard
(Corporate Broking)
RBC Capital Markets - Joint Tel: +44 (0) 20
Broker 7653 4000
Marcus Jackson / Elliot Thomas
/ Jack Wood
Instinctif Partners Tel: +44 (0) 20
7457 2020
Melanie Toyne-Sewell / Alex
Shaw / Deborah Bell Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing ethical access to medicines. Its mission is to deliver
the right medicine to the right patient at the right time through
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines. Clinigen acquired Quantum Pharma in
November 2017.
For more information, please visit www.clinigengroup.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHFKADKBBKDOBB
(END) Dow Jones Newswires
March 01, 2018 04:00 ET (09:00 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024